--- title: "Regencell Bioscience Holdings (RGC) news: offering" url: "https://aibio.space/companies/regencell-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RGC offering news: Regencell Bioscience agrees to $20.0 million registered direct offering at $20.30 a share." --- RGC Regencell Bioscience Holdings Limited NASDAQ · Hong Kong # Regencell Bioscience Holdings (RGC) news RGC offering news Financings · 2026-05-19 ## [Regencell Bioscience agrees to $20.0 million registered direct offering at $20.30 a share](https://aibio.space/news/regencell-bioscience-agrees-20-0-million-registered-direct-offering-20/) Regencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account. ## Latest Regencell Bioscience Holdings news We have not published a story on Regencell Bioscience Holdings yet. When there is news, it will appear here. ## Regencell Bioscience Holdings at a glance - **Ticker**: RGC - **Listing**: NASDAQ - **Country**: Hong Kong - **Cash, Jun 30, 2026**: $14.2 million ### Related companies - [Beijing Tong Ren Tang Chinese Medicine Co.](https://aibio.space/companies/beijing-tong-ren-tang-chinese-medicine/) HKEX: 3613 - [China Biotech Services Holdings](https://aibio.space/companies/china-biotech-services/) HKEX: 8037 - [Sino Biopharmaceutical](https://aibio.space/companies/sino-biopharmaceutical/) HKEX: 1177 - [China Regenerative Medicine International](https://aibio.space/companies/china-regenerative-medicine-international/) HKEX: 8158 - [InSilico Medicine Cayman TopCo](https://aibio.space/companies/insilico-medicine-cayman-topco/) HKEX: 3696 - [Grand Pharmaceutical Group](https://aibio.space/companies/grand-pharmaceutical/) HKEX: 512 - [Tianda Pharmaceuticals](https://aibio.space/companies/tianda-pharmaceuticals/) HKEX: 455 - [HUTCHMED (China)](https://aibio.space/companies/hutchmed-china/) HKEX: 13 ### Also on NASDAQ - [Boundless Bio](https://aibio.space/companies/boundless-bio/) BOLD - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) GTBP - [ProKidney](https://aibio.space/companies/prokidney/) PROK - [Atara Biotherapeutics](https://aibio.space/companies/atara-biotherapeutics/) ATRA - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR - [HCW Biologics](https://aibio.space/companies/hcw-biologics/) HCWB ## What Regencell Bioscience Holdings does Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on research, development and commercialization of traditional Chinese medicine (TCM) for neurocognitive disorders and degeneration, specifically ADHD and ASD. It conducts its TCM research and development through Regencell Bioscience Limited, a Hong Kong subsidiary, which has entered into Strategic Partnership Agreements and a Supplemental Agreement with a TCM practitioner. Regencell Bioscience Holdings is a Cayman Islands holding company with no substantive operations other than holding the shares of its subsidiaries. Its stated goal is to save and improve the lives of patients, their families and caregivers, and to become a market leader for the best natural and holistic treatment globally. The company held a 60% equity interest in a joint venture, Regencell Bioscience Asia Limited, which ceased business on December 31, 2023. The text says that disposition did not have a material impact on its results of operations. | Product or program | What it is | Stage | |---|---|---| | TCM programs for ADHD and ASD | Traditional Chinese medicine for neurocognitive disorders, specifically ADHD and ASD | | Summarised from the company's [20-F filed Oct 7, 2026](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/ea0307551-20f_regencell.htm). ## Regencell Bioscience Holdings annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | [$948,289](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | | Net income (loss) | [-$11.7 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | [-$3.6 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | | Cash from operations | [-$7.7 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | [-$3.1 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | | Cash and equivalents | [$14.2 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | | Short-term investments | | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/) | Latest balance sheet, Jun 30, 2026 (20-F): cash and equivalents $14.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Regencell Bioscience Holdings Has Regencell Bioscience Holdings raised money recently? Our latest story on this, dated May 19, 2026: "Regencell Bioscience agrees to $20.0 million registered direct offering at $20.30 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regencell-bioscience-agrees-20-0-million-registered-direct-offering-20/). What is the ticker symbol of Regencell Bioscience Holdings? Regencell Bioscience Holdings Limited trades under the ticker RGC on NASDAQ. Where is Regencell Bioscience Holdings listed? Regencell Bioscience Holdings Limited is listed on NASDAQ. What is the SEC CIK of Regencell Bioscience Holdings? The SEC Central Index Key (CIK) for Regencell Bioscience Holdings Limited is 1829667. Its filings are on SEC EDGAR. How many shares does Regencell Bioscience Holdings have outstanding? 495,884,376 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-10-07. Which country or territory is Regencell Bioscience Holdings listed under? Our directory records Regencell Bioscience Holdings Limited under Hong Kong. What does Regencell Bioscience Holdings do? Our directory classifies Regencell Bioscience Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Regencell Bioscience Holdings? The ISIN recorded for Regencell Bioscience Holdings Limited is KYG7487R1002. Does aibio.space cover Regencell Bioscience Holdings? aibio.space lists Regencell Bioscience Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Regencell Bioscience Holdings incorporated? SEC records list its state or country of incorporation as E9. What does Regencell Bioscience Holdings develop? Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on research, development and commercialization of traditional Chinese medicine (TCM) for neurocognitive disorders and degeneration, specifically ADHD and ASD. It conducts its TCM research and development through Regencell Bioscience Limited, a Hong Kong subsidiary, which has entered into Strategic Partnership Agreements and a Supplemental Agreement with a TCM practitioner. What is TCM programs for ADHD and ASD from Regencell Bioscience Holdings? TCM programs for ADHD and ASD: Traditional Chinese medicine for neurocognitive disorders, specifically ADHD and ASD Is Regencell Bioscience Holdings profitable? Regencell Bioscience Holdings Limited reported a net loss of $11.7 million for the fiscal year ended Jun 30, 2026, and used $7.7 million of cash in operations, per its annual report to the SEC. How much does Regencell Bioscience Holdings spend on research and development? $1.3 million in the fiscal year ended Jun 30, 2026, per its annual report. How much cash does Regencell Bioscience Holdings have? $14.2 million in cash at Jun 30, 2026, per its 20-F. ## Investor discussion: Regencell Bioscience Holdings Members talk about Regencell Bioscience Holdings (RGC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Regencell Bioscience Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/ea0307551-20f_regencell.htm) 2. 2026-05-19 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1829667/000121390026058749/ea029147201ex99-1.htm) 3. 2026-03-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1829667/000121390026035916/ea0282909-424b5_regencell.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RGC on TradingView](https://www.tradingview.com/symbols/NASDAQ-RGC/). ## SEC filings and registration - **SEC name**: Regencell Bioscience Holdings Ltd - **CIK**: 1829667 - **Industry (SIC)**: Medicinal Chemicals & Botanical Products (2833) - **US tickers**: RGC (Nasdaq) - **State or country of incorporation**: E9 - **Filer category**: Large accelerated filer - **Business address**: 9/F CHINACHEM LEIGHTON PLAZA, HONG KONG - **Phone**: 852 2155 0823 - **Shares outstanding**: 495,884,376 as of 2026-06-30 (20-F filed 2026-10-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [20-F](https://www.sec.gov/Archives/edgar/data/1829667/000121390026107581/ea0307551-20f_regencell.htm) filed 2026-10-07 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026060337/ea0291473-6k_regencell.htm) filed 2026-05-22 - [424B5](https://www.sec.gov/Archives/edgar/data/1829667/000121390026059114/ea0291272-424b5_regencell.htm) filed 2026-05-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026059056/ea0291463-6k_regencell.htm) filed 2026-05-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026058749/ea0291472-6k_regencell.htm) filed 2026-05-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026053892/ea0289605-6k_regencell.htm) filed 2026-05-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026045171/ea0286795-6k_regencell.htm) filed 2026-04-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1829667/000121390026035953/ea0283936-6k_regencell.htm) filed 2026-03-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001829667), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Regencell Bioscience Holdings Limited is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RGC, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Regencell Bioscience Holdings Limited - **Ticker**: RGC - **Listing**: NASDAQ - **Country or territory**: Hong Kong - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG7487R1002 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RGC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/regencell-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Regencell Bioscience Holdings (RGC) news: offering", 2026-10-31, https://aibio.space/companies/regencell-bioscience/